# A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Source: https://onco.cc/trials/nct07518147/  
OnCo record `nct07518147` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment is a phase 3 interventional study registered as NCT07518147 by Sichuan Baili Pharmaceutical Co., Ltd., with 438 participants planned, started 2026-05-15 and due to reach its primary completion in 2029-12. Interventions recorded: BL-M05D1, Paclitaxel, Docetaxel and Irinotecan hydrochloride.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07518147
- Phase: 3
- Setting: A Randomized Controlled Phase III Clinical Study Comparing BL-M05D1 for Injection With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) 18.2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-line Treatment
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 438

## Sources

- ClinicalTrials.gov NCT07518147: https://clinicaltrials.gov/study/NCT07518147

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07518147.json